創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 19/08/21 | GEM102 | Cyclodextrin derivative | Cancer | i.v. | Small molecule |
Preclinical | Modified Methyl-b-Cyclodextrin (CyD). Displayed potent antitumor activity in vitro, compared to M-β-CyD. Drastically inhibited tumor growth after a single intravenous injection to tumor-bearing mice, compared to doxorubicin and M-β-CyD, without any significant change in blood chemistry values. |
問合せ |
| 19/08/16 | GEM101 | Positive allosteric modulator of GABA-A receptor | Depression and PTSD | Intra-nasal | Peptide |
Preclinical | Exhibited robust mixed anxiolytic and antidepressant activity in vivo animal models. Increased neurogenesis 1 week after single injection. No decrease in locomotor activity, no sedation. |
問合せ |
| 19/08/16 | GEM100 | mGluR5 negative allosteric modulator | Depression and movement disorder | Intra-nasal | Peptide |
Preclinical | mGLuR5 leader peptide was discovered and in vivo efficacy confirmed. GEM100 specifically increases locomotor activity in rats, with no effects on behavior. |
問合せ |
| 19/08/16 | GEM099 | TrkB modulator | Depression | Intra-nasal | Peptide |
Preclinical | TrkB peptide modulator discovery was launched. | 問合せ |
| 19/08/13 | GEM098 | GnRH receptor antagonist | Endometriosis and Uterine fibroids | Oral | Small molecule |
Phase 1 | In Phase Ib, GEM098 showed dose-dependent suppression of LH, FSH and E2. The suppressive effects on E2 lasted up to 24 hrs and were more excellent when compared with the published phase 1 data of Elagolix in healthy premenopausal women. No serious adverse events were seen and well tolerated up to 320 mg QD. | 問合せ |
| 19/08/13 | GEM097 | Factor VIIa derivative | Bypassing therapy in hemophilia with inhibitors | i.v. | Protein |
IND ready | GEM097 is rFVIIa fused to transferrin and has longer half-lives than rFVIIa in rats and monkeys. A cleavable linker between rFVIIa and trasferrin of GEM097 allows minimal reducuction of FVIIa activity due to fusion. Preclinical (GLP) toxicity studies did not show any toxic evidence in rats or monkeys. | 問合せ |
| 19/07/31 | GEM096 | Progesterone receptor agonist | Recurrent preterm birth | Oral | Small molecule |
Phase 2 completed | Potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An end of Phase 2 meeting was completed with the FDA. |
問合せ |
| 19/07/31 | GEM095 | Androgen receptor agonist | NASH, Cirrhosis | Oral | Small molecule |
Phase 1 | An oral prodrug of bioidentical testosterone that is being developed as a treatment of cirrhotic non-alcoholic steatohepatitis (NASH). | 問合せ |
| 19/07/31 | GEM094 | Androgen receptor agonist | NASH, Pre-Cirrhosis | Oral | Small molecule |
Phase 2 ongoing | An oral prodrug of bioidentical testosterone that is being developed as a treatment of non-alcoholic steatohepatitis (NASH) and is being studied in the LifT Phase 2 clinical study in biopsy confirmed NASH subjects. | 問合せ |
| 19/07/31 | GEM093 | Androgen receptor agonist | Hypogonadism | Refer to Note | Small molecule |
Phase 2 completed | Route: Oral (QD) A novel next generation oral prodrug of testosterone with potential for once-daily oral dosing that has completed Phase 2 testing. |
問合せ |